Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09YJR
|
||||
| Drug Name |
S 18204
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Unspecified | Investigative | [1] | ||
| Formula |
C20H21ClNNaO4S
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Thromboxane A2 receptor | Target Info | Modulator | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Platelet activation | |||||
| Reactome | Prostanoid ligand receptors | ||||
| G alpha (q) signalling events | |||||
| G alpha (12/13) signalling events | |||||
| Thromboxane signalling through TP receptor | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Small Ligand GPCRs | |||||
| Signal amplification | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.